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As patient-oriented care has expanded in
health care, the use of patient-reported
outcomes (PROs) to evaluate patients’
health has increased as well. A PRO is
deﬁned by the US Food and Drug Ad-
ministration as “any report coming from
patients about a health condition and its
treatment, without interpretation of the
patient’s response by a clinician or any-
one else.”1,2 PROs can complement
more traditional, biologically based,
clinical measures of patients’ health,
such as BP or albuminuria, by adding
information about the patient’s percep-
tions of their own health. For example,
PROs measuring health-related quality
of life (HRQOL) look into how the pa-
tient feels (wellbeing) and what they can
do (functionality). HRQOL includes
physical, mental, and social health, and
provides a comprehensive view of how a
patient is affected by an illness like
ESKD. Applications for PROs in ESKD
include monitoring of individuals or
groups of patients in clinic, evaluating
the effectiveness of new treatments,
and performance and quality monitor-
ing of kidney clinics.
Implementation of PROs has begun
to yield beneﬁts in many ﬁelds, such as
oncology and orthopedics. For example,
in a landmark publication in JAMA of
patients with metastatic cancer who
were receiving routine chemotherapy,
Basch et al.2 found that electronic mon-
itoring of symptoms using PROs, and
sending alerts to clinicians when dis-
tressing symptoms were indicated, was
associated with improved patient sur-
vival compared with a control group
(hazard ratio for death, 0.83; 95% con-
ﬁdence interval, 0.70 to 0.99; P50.04).
Because the PRO-based electronic
symptom monitoring system used in
this study allowed for brief, easy-to-
complete symptom assessments, these
ﬁndings also point to efﬁciency gains in
patient management possible with
PROs. In orthopedics, because of their
salience in characterizing postsurgical
health and recovery,3 PROs capturing
physical functioning have been em-
braced by the American Orthopedic
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Foot and Ankle Society and are admin-
istered systematically in ten clinical sites
throughout the United States and
included in a registry.4 This example
demonstrates the value of PROs in cap-
turing the outcomes both patients and
clinicians value, and how these out-
comes can be used in population health
monitoring.
There is opportunity for increased ap-
plication of PROs to improve clinical
monitoring of patients’ health and treat-
ment evaluation in ESKD. Previous
research comparing disease burden of
several chronic conditions found that
patients with ESKD had worse physi-
cal functioning than any of the other
conditions included in the study (e.g.,
diabetes, symptomatic AIDS), with the
exception of multiple sclerosis.5 The re-
cent work of the Standardized Outcomes
in Nephrology group has corroborated
these ﬁndings and demonstrated that
ESKD patients and caregivers prioritize
outcomes like fatigue, ability to travel,
overall effect of ESKD on the family,
and ability to work over more traditional
outcomes such as mortality and hospi-
talizations.6 The time is ripe to expand
and reﬁne the use of PROs with patients
with ESKD.
One issue facing ESKD clinicians and
researcherswhowould like tousePROs is
whether to use a measure with content
targeted speciﬁcally toward ESKD-
related health issues or “universal” (ge-
neric) measures that apply equally well
to patients with all types of chronic con-
ditions. On one hand, there is some ev-
idence that disease-targeted measures
are more sensitive and responsive to
change. For example, in this issue of
the Journal of the American Society of
Nephrology (JASN), Ware et al.7 ﬁnd that
a new disease-targeted measure, the CKD
Quality of Life instrument, ismore respon-
sive to differences in health among patients
with CKD than the Medical Outcomes
Study Short Form 12 summary measures,
the Physical Component Summary (PCS),
and the Mental Component Summary
(MCS). Yet, there are important beneﬁts
to using a generic measure as well.
Among the most important of these
beneﬁts is the ability to establish a
common metric for comparison of
HRQOL and symptoms across multiple
conditions, or to capture relevant as-
pects of HRQOL for patients with mul-
tiple chronic conditions, as is the case
for the vast majority of patients with
ESKD. Of course, one reasonable ap-
proach may be to include both generic
and kidney-disease targeted scales in a
single instrument. This is the approach
taken by the widely used Kidney Disease
Quality of Life (KDQOL) scales, which
include Medical Outcomes Study Short
Form 12 or 36 items, depending on the
version of the KDQOL.8,9 Peipert et al.,
in this issue of JASN, advance the inter-
pretability of the KDQOL-36 measure
by providing normative values refer-
enced to the national United States dial-
ysis population, as well as support for a
new, single-score composite using the
KDQOL-36’s items.10
Whether accompanied by kidney-tar-
geted measures or used on their own,
PROs focused on generic HRQOL are
relevant to ESKD. This is especially the
case for the National Institutes of
Health’s Patient-Reported Outcomes
Measurement Information System
(PROMIS) suite of measures. PROMIS
has been innovative in multiple ways.
PROMIS measures use item response
theory and can be administered through
computer adaptive testing, which draws
from large banks of questions to gener-
ate reliable and parsimonious measures
of patients’ HRQOL across multiple
physical, mental, and social domains.11
All PROMIS measures are scored on a
user-friendly T-score metric with a
mean value of 50 and SD of 10, normed
to the United States general population.
This scoring approach allows any indi-
vidual’s or group’s score on PROMIS
measures to be compared with the aver-
age individual from the United States
general population. For instance, if a pa-
tient with ESKD scores 40 on a PROMIS
physical function measure in the
clinic, a clinician knows immediately
that the patient’s level of physical function
is 1 SD below the United States general
population value, which may indicate
clinically signiﬁcant dysfunction. Every
PROMIS measure is brief and poses little
burden on respondents; average comple-
tion times of ,1 minute for PROMIS
computer adaptive testing have been
documented.12 Critically, all PROMIS
measures are free to use and available to
the public. Users can browse PROMIS
measures at http://www.healthmeasures.
net/, then download paper versions
of each instrument and supporting
documentation without registration.
However, many users will ﬁnd elec-
tronic implementations of PROMIS
measures in the electronic medical re-
cord via Epic and Research Electronic
Data Capture (REDCap) software to be
most efﬁcient.
Despite the signiﬁcant beneﬁts of-
fered by PROMIS, these measures have
been infrequently used among patients
with ESKD,with the exception of notable
implementations among the Midwest
Pediatric Nephrology Consortium13
and kidney transplant patients.14 Noting
the extensive opportunity and need to
routinely assess HRQOL among patients
on dialysis, there is a much larger role
for PROMIS measures in ESKD. One
way to fulﬁll this role is to replace the
Short Form-12 PCS and MCS in the
KDQOL-36, which is among the most
commonly used measures to fulﬁll the
Centers for Medicare and Medicaid Ser-
vices requirement to assess HRQOL on
an annual basis. This transition could
be eased by the ability to create a “cross-
walk” linking PCS and MCS scores to
PROMIS measures using advanced psy-
chometric approaches, which has al-
ready been accomplished for multiple
legacy measures in PROMIS15–17 and as
part of the PROsetta Stone initiative
(http://www.prosettastone.org/Pages/
default.aspx).
Whether using PROMIS measures
or others, patients with ESKD stand to
beneﬁt signiﬁcantly from a variety
of new clinical and evaluation opportu-
nities with PROs. Doing so will help
align ESKD care with patient priorities
and open up new, efﬁcient channels
for provider–patient communication.
The burden of disease for patients with
ESKD is formidable and affects many as-
pects of patients’ lives. Adopting PRO-
based approaches to manage the health
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